<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927950</url>
  </required_header>
  <id_info>
    <org_study_id>2007-002649-19</org_study_id>
    <secondary_id>7043</secondary_id>
    <secondary_id>SF0180125s08</secondary_id>
    <nct_id>NCT03927950</nct_id>
  </id_info>
  <brief_title>Investigation of Genetic Predictors of the Response to Selective Serotonin Re-uptake Inhibitors (SSRI) Treatment</brief_title>
  <official_title>Investigation of Genetic Predictors of the Response to SSRI Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antidepressant medications are among the most commonly prescribed pharmacological agents
      in patients with mood and anxiety disorder. Despite recent advances in antidepressant
      pharmacotherapy, there is a pressing need for substantial optimization and improvment of
      outcome of pharmacotherapy of psychiatric disorders by providing individualized and
      science-based treatment guidelines. Besides it is rather difficult in clinical practice to
      predict, which patient will response to a certain pharmacological treatment well and which
      one less so. Putative predictors of response to antidepressant include demographic and
      clinical characteristics, personality traits, biological markers and psychophysiological
      features. Recently the research studies shown that divergences in antidepressant efficacy may
      be related to genetic variations of patients. The pharmacogenetic studies have multiplied in
      recent decade due to the impact that such studies may have in everyday clinical practice once
      reliable predictors could be identified. The pharmacogenetic research using new DNA
      microarray-based technology can reasonably be expected to contribute to the prediction of
      likelihood of treatment response and risk of development of adverse side effects in
      individual patients in case of antidepressant treatment. By reducing costly treatment
      failures and the likelihood of serious adverse events, pharmacogenetic testing may help to
      improve the treatment possibilities for chronic diseases, reduce the burden prescription drug
      costs, and lower the costs of drug development. The further detailed investigation of
      peripheral gene expression profiles may help to identify responsible genes that underlie the
      process of development of affective disorders and open novel horizons for understanding
      molecular mechanisms of psychopharmacological treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To participate in the study the subjects must be at least 18 years old and give a written
      informed consent after an oral and written explanation of the study aims and methods. The
      study sample will include the female and male patients with panic disorder or major
      depression diagnosis according to DSM-IV criteria. Patients will be recruited from the out-
      and inpatients services of the Psychiatric Clinic of the Tartu University Hospital. For the
      detailed assessment of clinical severity of specific disorder and treatment effects the
      disorder-specific rating scales: Montgomery-Asberg's Depression Rating Scale (MADRS),
      Clinical Global Impression scale (CGI) will be used. The adverse effects will be evaluated by
      letting the patients to fill the checklist of side-symptoms. In both patient groups (with
      panic disorder and major depression) an SSRI escitalopram (Cipralex) will be administrated
      for 12 weeks in flexible dose ranging between 10 - 20 mg/per day. At the end of week 12 the
      patients will defined as responders if the decrease in MADRS scores is at least 50% and score
      on the CGI improvement scale is 2 or less. The remitters will defined if the scores are less
      than 12 on the MADRS. Patients who do not meet these criteria will defined as non-responders
      and non-remitters respectively. Depressive patients, showing non-response to escitalopram
      monotherapy will given the combination of 20 mg of escitalopram and 150-300 mg of bupropion
      (Wellbutrin SR) for 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg's Depression Rating Scale</measure>
    <time_frame>the results are for a single time point (12 weeks)</time_frame>
    <description>Ten-item diagnostic questionnaire to measure the severity of depressive symptoms. The lowest possible score on the scale is 0 and the highest possible score is 60. The lowest possible score on the scale represents &quot;the lack of any depressive symptoms&quot; and the highest score represents the &quot;severe depressive symptoms&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>The outcome was measured at the week 12</time_frame>
    <description>17-item diagnostic questionnaire to measure the severity of depressive symptoms. The lowest possible score on the scale is 0 and the highest possible score is 52. The lowest possible score on the scale represents &quot;the lack of any depressive symptoms&quot; and the highest score represents the &quot;severe depressive symptoms&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>Escitalopram bupropion open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>escitalopram 10-20mg per day 12 weeks</description>
    <arm_group_label>Escitalopram bupropion open-label</arm_group_label>
    <other_name>Cipralex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion</intervention_name>
    <description>bupropion 150-300mg per day 6 weeks</description>
    <arm_group_label>Escitalopram bupropion open-label</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders

          -  Diagnosis according to DSM-IV criteria

          -  At severity of depression of at least moderate as indicated by a Montgomery-Asberg's
             Depression Rating Scale (MADRS) total score of 22 or higher

          -  Only secondary current comorbid anxiety disorder

        Exclusion Criteria:

          -  Bipolar disorder

          -  Psychotic disorder or features

          -  Current eating disorders

          -  Mental retardation

          -  Any pervasive developmental disorder or cognitive disorder

          -  Alcohol or drug abuse-related disorders within 12 months prior to baseline

          -  Acute infections, neurological or any other unstable general disorders, serious
             suicide risk, formal behaviour therapy, or systematic psychotherapy, pregnancy or
             breastfeeding

          -  A history of hypersensitivity or non-response to escitalopram or bupropion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduard Maron, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, University of Tartu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Tartu</name>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <link>
    <url>http://www.ravimiamet.ee/</url>
    <description>State Agency of Medicines</description>
  </link>
  <link>
    <url>http://www.kliinikum.ee/psyhhiaatriakliinik/</url>
    <description>Department of Psychiatry</description>
  </link>
  <link>
    <url>http://www.ut.ee</url>
    <description>University of Tartu</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <results_first_submitted>February 2, 2009</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2019</results_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Eduard Maron</investigator_full_name>
    <investigator_title>Department of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Treatment efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Department of Psychiatry</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Escitalopram Bupropion Open-label</title>
          <description>Escitalopram 10-20mg and Bupropion 150-300mg; an open-label, placebo not controlled trial in a naturalistic setting</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Escitalopram</title>
          <description>Escitalopram 10-20mg; an open-label, placebo not controlled trial in a naturalistic setting</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Rating Scale for Depression</title>
        <description>17-item diagnostic questionnaire to measure the severity of depressive symptoms. The lowest possible score on the scale is 0 and the highest possible score is 52. The lowest possible score on the scale represents &quot;the lack of any depressive symptoms&quot; and the highest score represents the &quot;severe depressive symptoms&quot;.</description>
        <time_frame>The outcome was measured at the week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram</title>
            <description>Escitalopram 10-20mg; an open-label, placebo not controlled trial in a naturalistic setting</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression</title>
          <description>17-item diagnostic questionnaire to measure the severity of depressive symptoms. The lowest possible score on the scale is 0 and the highest possible score is 52. The lowest possible score on the scale represents &quot;the lack of any depressive symptoms&quot; and the highest score represents the &quot;severe depressive symptoms&quot;.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Montgomery-Asberg's Depression Rating Scale</title>
        <description>Ten-item diagnostic questionnaire to measure the severity of depressive symptoms. The lowest possible score on the scale is 0 and the highest possible score is 60. The lowest possible score on the scale represents &quot;the lack of any depressive symptoms&quot; and the highest score represents the &quot;severe depressive symptoms&quot;.</description>
        <time_frame>the results are for a single time point (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Escitalopram Bupropion Open-label</title>
            <description>Escitalopram 10-20mg and Bupropion 150-300mg; an open-label, placebo not controlled trial in a naturalistic setting</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery-Asberg's Depression Rating Scale</title>
          <description>Ten-item diagnostic questionnaire to measure the severity of depressive symptoms. The lowest possible score on the scale is 0 and the highest possible score is 60. The lowest possible score on the scale represents &quot;the lack of any depressive symptoms&quot; and the highest score represents the &quot;severe depressive symptoms&quot;.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During course of trial (12 weeks)</time_frame>
      <desc>9 patients discontinued escitalopram treatment due to side effects (5 due to nausea, 4 due to sexual dysfunction)</desc>
      <group_list>
        <group group_id="E1">
          <title>Escitalopram Bupropion Open-label</title>
          <description>Escitalopram 10-20mg Bupropion 150-300mg; an open-label, placebo not controlled trial in a naturalistic setting</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eduard Maron</name_or_title>
      <organization>Department of Psychiatry, University of Tartu</organization>
      <phone>+3727318812</phone>
      <email>eduard.maron@kliinikum.ee</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

